Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 4/20 | 0.33 |
| ▸ | FNTB | P49356 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284114 | 0.93 | MCHR1 (0.35) | MCHR1FNTAFNTBTSHRIRAK4 | |
| SCHEMBL4285115 | 0.80 | CA1 (0.35) | MCHR1IRAK4 | |
| SCHEMBL4292497 | 0.76 | KMO (0.49) | MCHR1TSHRALDH1A1MAPK1 | |
| SCHEMBL4286425 | 0.75 | CA1 (0.36) | MCHR1IRAK4HDAC8 | |
| SCHEMBL4753396 | 0.75 | CA1 (0.36) | MCHR1IRAK4HDAC8 | |
| SCHEMBL4284550 | 0.72 | TEAD1 (0.46) | TSHRALDH1A1MAPK1 | |
| SCHEMBL4285897 | 0.71 | KMO (0.51) | TSHRALDH1A1MAPK1 | |
| SCHEMBL4281778 | 0.71 | RAB9A (0.52) | TSHRALDH1A1 | |
| SCHEMBL4288884 | 0.71 | ADRA2A (0.52) | TSHRALDH1A1 | |
| SCHEMBL4281324 | 0.71 | PDE10A (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MCHR1 3701/4885FNTA 1157/4885FNTB 2585/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MCHR1 3701/4885FNTA 1157/4885FNTB 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.